Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06388187
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-04-24
Brief Title:
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Efficacy and Safety of Cagrilintide sc in Combination With Semaglutide scCagriSema sc 10 mg10 mg and 17 mg17 mg Once-weekly in Participants With Overweight or Obesity
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will look at how well CagriSema helps people with excess body weight lose weight CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide CagriSema cannot yet be prescribed by doctors In the study participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance The study will last for about 1½ years for each participant
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-509273-24 | OTHER | European Medical Agency EMA | None |
| U1111-1298-3451 | OTHER | None | None |